A 3 0-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and / or metastatic head and neck squamous cell carcinoma
暂无分享,去创建一个
J. Weidhaas | C. Chung | E. Fertig | R. Slebos | J. Gilbert | B. Murphy | R. Jordan | B. Burtness | M. Considine | J. Howard | A. Forastiere | H. Kang | T. Paranjape | J. Lee | S. Nallur | J. Garcia | J. Pérez